Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Deerfield Capital Management
AddedFeb 13, 2024
UpdatedJun 28, 2026
Deerfield Capital Management

Deerfield Capital Management

Operating

DCM: A global fixed-income investment adviser and business services provider since 1993.

Location
Chicago, IL, US
Founded
1994
Firm
Compare
Portfolio
Employees

Investments

Adaptive Phage Therapeutics
Adaptive Phage Therapeutics

Total Raised

$131.7M

Rounds

9

Series B$12MJune 2023
Epic Sciences
Epic Sciences

Total Raised

$219.5M

Rounds

8

Series G$24MApril 2023
Series E$52MSeptember 2018
ConcertoCare
ConcertoCare

Total Raised

$150.2M

Rounds

4

Series B$105MFebruary 2022
Series Unknown$30MNovember 2016
Quartet Health
Quartet Health

Total Raised

$265.9M

Rounds

7

Series D$7.5MDecember 2019
Series C$40MJanuary 2018
Revolution Medicines
Revolution Medicines
Public

Total Raised

$1.1B

Rounds

8

Series C$100MJuly 2019
Acutus Medical
Acutus Medical
Acquired

Total Raised

$343.2M

Rounds

10

Debt Financing$70MJune 2019
Series D$100MJune 2019
Stelexis Therapeutics
Stelexis Therapeutics

Total Raised

$43M

Rounds

1

Series A$43MJanuary 2019
Ribon Therapeutics
Ribon Therapeutics

Total Raised

$259M

Rounds

7

Series B$65MJanuary 2019
Mirum Pharmaceuticals
Mirum Pharmaceuticals
Public

Total Raised

$497M

Rounds

5

Series A$120MNovember 2018
NeoChord
NeoChord

Total Raised

$89.9M

Rounds

13

Series D$25MNovember 2018
Allogene Therapeutics
Allogene Therapeutics
Public

Total Raised

$781.8M

Rounds

4

Convertible Note$120MSeptember 2018
Alector
Alector
Public

Total Raised

$269.5M

Rounds

7

Series E$133MJuly 2018
Appello Pharmaceuticals
Appello Pharmaceuticals

Total Raised

$29M

Rounds

2

Series A$15.5MJune 2018
Strata Oncology
Strata Oncology

Total Raised

$128M

Rounds

3

Series B$26MMay 2018
Fog Pharmaceuticals
Fog Pharmaceuticals

Total Raised

$385.3M

Rounds

5

Series B$66MMay 2018
Braeburn
Braeburn

Total Raised

$133M

Rounds

2

Debt Financing$110MJanuary 2018
Johns Hopkins University
Johns Hopkins University

Total Raised

$186.5M

Rounds

6

Series Unknown$65MNovember 2017
Conventus Orthopaedics
Conventus Orthopaedics

Total Raised

$176.1M

Rounds

10

Series C$20MMay 2017
Rhythm Pharmaceuticals
Rhythm Pharmaceuticals
Public

Total Raised

$895.5M

Rounds

11

Series Unknown$41MFebruary 2017
Invitae
Invitae
Public

Total Raised

$2.5B

Rounds

14

Series F$120MOctober 2014
Nuo Therapeutics
Nuo Therapeutics
Public

Total Raised

$118.3M

Rounds

14

Post Ipo Debt$35MJune 2014